120 related articles for article (PubMed ID: 37348363)
1. Exosome-mediated small interfering RNA delivery inhibits aberrant osteoblast differentiation in Apert syndrome model mice.
Myo AC; Kobayashi Y; Niki Y; Kamimoto H; Moriyama K
Arch Oral Biol; 2023 Sep; 153():105753. PubMed ID: 37348363
[TBL] [Abstract][Full Text] [Related]
2. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome.
Tanimoto Y; Yokozeki M; Hiura K; Matsumoto K; Nakanishi H; Matsumoto T; Marie PJ; Moriyama K
J Biol Chem; 2004 Oct; 279(44):45926-34. PubMed ID: 15310757
[TBL] [Abstract][Full Text] [Related]
3. Aberrantly activated Wnt/β-catenin pathway co-receptors LRP5 and LRP6 regulate osteoblast differentiation in the developing coronal sutures of an Apert syndrome (Fgfr2
Min Swe NM; Kobayashi Y; Kamimoto H; Moriyama K
Dev Dyn; 2021 Mar; 250(3):465-476. PubMed ID: 32822074
[TBL] [Abstract][Full Text] [Related]
4. Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts.
Suzuki H; Suda N; Shiga M; Kobayashi Y; Nakamura M; Iseki S; Moriyama K
J Cell Physiol; 2012 Sep; 227(9):3267-77. PubMed ID: 22105374
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis.
Yokota M; Kobayashi Y; Morita J; Suzuki H; Hashimoto Y; Sasaki Y; Akiyoshi K; Moriyama K
PLoS One; 2014; 9(7):e101693. PubMed ID: 25003957
[TBL] [Abstract][Full Text] [Related]
6. Dura in the pathogenesis of syndromic craniosynostosis: fibroblast growth factor receptor 2 mutations in dural cells promote osteogenic proliferation and differentiation of osteoblasts.
Ang BU; Spivak RM; Nah HD; Kirschner RE
J Craniofac Surg; 2010 Mar; 21(2):462-7. PubMed ID: 20489451
[TBL] [Abstract][Full Text] [Related]
7. Excessive osteoclast activation by osteoblast paracrine factor RANKL is a major cause of the abnormal long bone phenotype in Apert syndrome model mice.
Shin HR; Kim BS; Kim HJ; Yoon H; Kim WJ; Choi JY; Ryoo HM
J Cell Physiol; 2022 Apr; 237(4):2155-2168. PubMed ID: 35048384
[TBL] [Abstract][Full Text] [Related]
8. Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse model.
Morita J; Nakamura M; Kobayashi Y; Deng CX; Funato N; Moriyama K
Dev Dyn; 2014 Apr; 243(4):560-7. PubMed ID: 24259495
[TBL] [Abstract][Full Text] [Related]
9. Effects of FGFR Signaling on Cell Proliferation and Differentiation of Apert Dental Cells.
Lu C; Huguley S; Cui C; Cabaniss LB; Waite PD; Sarver DM; Mamaeva OA; MacDougall M
Cells Tissues Organs; 2016; 201(1):26-37. PubMed ID: 26613250
[TBL] [Abstract][Full Text] [Related]
10. The study of abnormal bone development in the Apert syndrome Fgfr2+/S252W mouse using a 3D hydrogel culture model.
Yang F; Wang Y; Zhang Z; Hsu B; Jabs EW; Elisseeff JH
Bone; 2008 Jul; 43(1):55-63. PubMed ID: 18407821
[TBL] [Abstract][Full Text] [Related]
11. Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.
Wang Y; Sun M; Uhlhorn VL; Zhou X; Peter I; Martinez-Abadias N; Hill CA; Percival CJ; Richtsmeier JT; Huso DL; Jabs EW
BMC Dev Biol; 2010 Feb; 10():22. PubMed ID: 20175913
[TBL] [Abstract][Full Text] [Related]
12. P253R fibroblast growth factor receptor-2 mutation induces RUNX2 transcript variants and calvarial osteoblast differentiation.
Baroni T; Carinci P; Lilli C; Bellucci C; Aisa MC; Scapoli L; Volinia S; Carinci F; Pezzetti F; Calvitti M; Farina A; Conte C; Bodo M
J Cell Physiol; 2005 Feb; 202(2):524-35. PubMed ID: 15389579
[TBL] [Abstract][Full Text] [Related]
13. Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis.
Lemonnier J; Haÿ E; Delannoy P; Lomri A; Modrowski D; Caverzasio J; Marie PJ
J Bone Miner Res; 2001 May; 16(5):832-45. PubMed ID: 11341328
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling.
Miraoui H; Oudina K; Petite H; Tanimoto Y; Moriyama K; Marie PJ
J Biol Chem; 2009 Feb; 284(8):4897-904. PubMed ID: 19117954
[TBL] [Abstract][Full Text] [Related]
15. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis.
Yin L; Du X; Li C; Xu X; Chen Z; Su N; Zhao L; Qi H; Li F; Xue J; Yang J; Jin M; Deng C; Chen L
Bone; 2008 Apr; 42(4):631-43. PubMed ID: 18242159
[TBL] [Abstract][Full Text] [Related]
16. Increased EFG- and PDGFalpha-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis.
Miraoui H; Ringe J; Häupl T; Marie PJ
Hum Mol Genet; 2010 May; 19(9):1678-89. PubMed ID: 20124286
[TBL] [Abstract][Full Text] [Related]
17. PIN1 is a new therapeutic target of craniosynostosis.
Shin HR; Bae HS; Kim BS; Yoon HI; Cho YD; Kim WJ; Choi KY; Lee YS; Woo KM; Baek JH; Ryoo HM
Hum Mol Genet; 2018 Nov; 27(22):3827-3839. PubMed ID: 30007339
[TBL] [Abstract][Full Text] [Related]
18. A role for fibroblast growth factor receptor-2 in the altered osteoblast phenotype induced by Twist haploinsufficiency in the Saethre-Chotzen syndrome.
Guenou H; Kaabeche K; Mée SL; Marie PJ
Hum Mol Genet; 2005 Jun; 14(11):1429-39. PubMed ID: 15829502
[TBL] [Abstract][Full Text] [Related]
19. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts.
Mansukhani A; Bellosta P; Sahni M; Basilico C
J Cell Biol; 2000 Jun; 149(6):1297-308. PubMed ID: 10851026
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of protein kinase Calpha, interleukin-1alpha, and RhoA guanosine 5'-triphosphatase in osteoblasts expressing the Ser252Trp fibroblast growth factor 2 receptor Apert mutation: identification by analysis of complementary DNA microarray.
Lomri A; Lemonnier J; Delannoy P; Marie PJ
J Bone Miner Res; 2001 Apr; 16(4):705-12. PubMed ID: 11315998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
